Skip to main content
. 2024 Oct 16;16:1759720X241289391. doi: 10.1177/1759720X241289391

Figure 2.

Figure 2.

Monthly average hospital costs per patient 9 months before and after the switch from originator to biosimilar adalimumab. The black dotted line indicates the date of the switch. y-axis: mean cost per patient per month (unadjusted). Number of patients in each biosimilar treatment group: GP2017 (n = 621) and SB5 (n = 695).